RHB-103 (Migraine) - Forecast and Market Analysis to 2023
|出版日期||內容資訊||英文 54 Pages
|RHB-103(偏頭痛治療藥):市場預測與分析 RHB-103 (Migraine) - Forecast and Market Analysis to 2023|
|出版日期: 2014年03月31日||內容資訊: 英文 54 Pages||
RedHill Biopharma (RedHill)是和IntelGenx共同開發，活用該公司專利薄膜技術「VersaFilm」來開發Rizatriptan薄膜劑(RHB-103)。Rizatriptan是以5-HT1B·5-HT1D受體的部份為標的的triptan類藥劑。5-HT1B·5-HT1D受體位於腦外/腦內血管(偏頭痛發生時的膨脹部位)、三叉神經系統的神經末端位置。這些受體阻斷劑可限制腦內血管，阻止神經肽的釋放，減輕三叉神經上的疼痛傳送。
The migraine market is saturated with generic drugs, and the remaining branded products already on the market are expected to lose exclusivity during the next few years, with the exception of Botox for chronic migraine, which is expected to maintain its leading position in terms of sales. However, reformulations of mature products as well as new classes of therapies are anticipated to launch during the forecast period and these will contribute to the market growth. By 2023, the migraine market will grow to $3.7 billion at a compound annual growth rate (CAGR) of 3.6%, with the US continuing to dominate the market as a result of higher drug prices and a large migraine population. Some of the new treatments are expected to target the key unmet needs but opportunities will remain for further treatment choices especially drugs that will offer an improved safety and side-effects profile.
RedHill Biopharma (RedHill) is co-developing rizatriptan film (RHB-103) with IntelGenx, using the latter's VersaFilm propriety thin film technology. Rizatriptan belongs to the triptan class of drugs which target the 5-HT1B and 5-HT1D receptor subtypes. These are located on the extracerebral, intracranial blood vessels, which dilate during the migraine attack, and also located on the nerve terminals of the trigeminal system. Inhibition of these receptors constricts cranial vessels, blocks neuropeptide release and reduces neurotransmission in the trigeminal pain pathways.